Pharmafile Logo
Pharmafocus logo
Advanced Search

Boehringer

Showing 15 posts of 150 posts found.

BI image

Boehringer and Sanofi admit to code breaches

February 13, 2015
Medical Communications, Sales and Marketing ABPI, Boehringer, PMCPA, Sanofi, afatinib, giotrif

Sanofi and Boehringer Ingelheim have both admitted to breaching the ABPI Code of Practice, with Sanofi set to be publicly …

News
Glyxambi image

Boehringer and Lilly score FDA yes for Glyxambi

February 3, 2015
Sales and Marketing Boehringer, FDA, Glyxambi, Tradjenta, empagliflozin, jardiance, lilly, linagliptin

The FDA has approved Glyxambi (empagliflozin/linagliptin), which has become the first combination of two diabetes drugs in their different classes …

News
Ofev image

Boehringer gains EU approval for Ofev

January 19, 2015
Sales and Marketing Boehringer, Esbriet, IPF, InterMune, ingelheim, nintedanib, ofev

The European Commission has approved Boehringer Ingelheim’s Ofev as a treatment for idiopathic pulmonary fibrosis (IPF). The approval follows the …

News
Strivrerdi image

Boehringer complaint ruled out by PMCPA

January 15, 2015
Medical Communications, Sales and Marketing ABPI, Boehringer, COPD, PMCPA, Striverdi, olodaterol

A complaint made by a pharmacist stating that the artwork image for Boehringer Ingelheim’s COPD drug Striverdi is misleading has …

News
BI image

Sanofi and Boehringer partner on biologics manufacturing

January 15, 2015
Manufacturing and Production, Sales and Marketing Boehringer, Sanofi, antibodies, biologics, cardiovascular, diabetes, mabs, manufacturing, monoclonal, oncology

Boehringer Ingelheim will help Sanofi extend its manufacturing capabilities for biologics in a new alliance, the companies have announced. Boehringer’s …

News
Pradaxa image

Boehringer gets NICE nod for Pradaxa

December 16, 2014
Sales and Marketing Boehringer, NHS, NICE, Pradaxa, VTE, dagibatran, ingelheim, warfarin

NICE has confirmed a recommendation for Boehringer Ingelheim’s controversial anti-blood clotting drug Pradaxa, as a treatment for blood clots in …

News
Boehringer image

Boehringer trials Pradaxa anti-bleeding antidote

December 11, 2014
Sales and Marketing BMS, Bayer, Boehringer, Eliquis, Pradaxa, ash, dabigatran, idarucizumab

Boehringer Ingelheim says that its investigational drug can safely reverse the blood-thinning effect of its anti-clotting drug Pradaxa (dabigatran). The …

News
BI image

Boehringer’s lung cancer drug Vargatef sees EU approval

November 28, 2014
Sales and Marketing Boehringer, EU, Europe, IPF, NSCLC, lung cancer, nintedanib, ofev, vargatef

Boehringer Ingelheim’s nintedanib has received its second nod in Europe this month with the European Commission approving it for the …

News
BI image

CHMP nods several drugs through

November 24, 2014
Sales and Marketing Boehringer, CHMP, EMA, Esbriet, FDA, Sanofi, nintedanib, ofev

Ten new medicines have been recommended for approval by the EMA’s Committee for Medicinal Products for Human Use (CHMP), among …

News

Reprieve for Boehringer plant as Chinese buyer comes forward

November 3, 2014
Manufacturing and Production Boehringer, China, Petersburg, UniTao Pharmaceuticals

A US manufacturing facility cued up for closure by Boehringer Ingelheim has been bought by a Chinese drugmaker. Boehringer had …

News
Pradaxa image

NICE recommends new indication for troubled Pradaxa

October 31, 2014
Sales and Marketing Boehringer, NHS, NICE, Pradaxa, dabigatran, ingelheim, warfarin

NICE has recommended Boehringer Ingelheim’s controversial anti-blood clotting drug Pradaxa for treating and preventing potentially-fatal blood clots in the legs …

News
Boehringer image

Boehringer seeks more indications for IPF drug

October 22, 2014
Research and Development, Sales and Marketing Boehringer, IPF, NSCLC, colectoral, crc, nintedanib, ofev

Boehringer Ingelheim’s nintedanib has entered Phase III studies for the treatment of colorectal cancer (CRC), which could add to the …

News
Boehringer image

Boehringer and Roche IPF drugs win FDA approval

October 16, 2014
Research and Development, Sales and Marketing Boehringer, ERS, Esbriet, FDA, IPF, InterMune, Roche, US, lung scarring, lungs, ofev

The FDA has approved both Roche’s Esbriet (pirfenidone) and Boehringer Ingelheim’s Ofev (nintedanib) for the treatment of the fatal lung …

News

Gamification: what’s in it for the pharma industry?

October 6, 2014
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AF, Boehringer, COPD, CRUK, Gamification, ROI, Syrum, digital

Gamification is the new buzzword in digital marketing and has the potential to engage consumers more than traditional strategies. This …

Feature

Boehringer spends €100 million on inhaler

September 30, 2014
Manufacturing and Production, Sales and Marketing Boehringer, Germany, Spiriva, Striverdi, inhaler, olodaterol, respimat

Boehringer Ingelheim is to spend more than €100 million at its Dortmund site in Germany in order to expand the …

News

Latest content

FDA accepts NDA for Karuna’s schizophrenia treatment

November 30, 2023

Vivos Therapeutics gains FDA 510(k) clearance for sleep apnea treatment device

November 30, 2023

Tolremo doses first patient in phase 1 trial for drug to combat transcriptional cancer drug resistance

November 29, 2023

FDA grants breakthrough device designation to Inflammatix’s TriVerity Acute Infection and Sepsis Test System

November 29, 2023

FDA accepts new drug application for Orexo’s opioid overdose medication

November 28, 2023